Gilles Guillon

Inhibition of oxytocin receptor function by direct binding of progesterone

Eric Grazzini, Gilles Guillon, Bernard Mouillac et al. · Nature · 1998 · 469 citations

Medicine, Endocrinology, Pharmacology +14

Vasopressin antagonists allow demonstration of a novel type of vasopressin receptor in the rat adenohypophysis.

Serge Jard, Rolf C. Gaillard, Gilles Guillon et al. · Molecular Pharmacology · 1986 · 273 citations

Life Sciences, Pharmacology, Physiology +15

Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.

C. Serradeil‐Le Gal, C Lacour, G Valette et al. · Journal of Clinical Investigation · 1996 · 249 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +11

Angiotensin II and dopamine modulate both cAMP and inositol phosphate productions in anterior pituitary cells. Involvement in prolactin secretion.

A Enjalbert, Fritz Sladeczek, Gilles Guillon et al. · Journal of Biological Chemistry · 1986 · 244 citations · Full text

Life Sciences, Endocrinology, Physiology +17

Characterization of (2 S,4 R)-1-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a Selective and Orally Active Vasopressin V1b Receptor Antagonist

Claudine Serradeil‐Le Gal, Jean Wagnon, Jacques Simiand et al. · Journal of Pharmacology and Experimental Therapeutics · 2002 · 210 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +14